Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Kura Oncology (NASDAQ:KURA) released its quarterly earnings data on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03), Briefing.com reports. During the same period in the prior year, the business earned ($0.50) EPS. The company’s revenue was up .0% on a year-over-year basis.

Kura Oncology Trading Up 0.2 %

Shares of KURA stock opened at $20.63 on Friday. The business’s fifty day moving average price is $20.66 and its 200 day moving average price is $15.99. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KURA. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Friday. JMP Securities lifted their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a report on Wednesday, January 31st. Finally, StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.